Biotech M&A by Slow Simmer: An Inside Look at the Build to Buy Deal
Jason Campagna Here’s a question for consideration: What does it mean to acquire a virtual, single asset biotech that was ‘built’ for the sole purpose of being bought? The answer (Read more...)
View ArticleKicking the Cyber Attack Can Down the Road
Michael Schrage By far the most important issue where the can got “kicked down the road” is any kind of concerted effort to deter or dissuade cross-border cyber-crime, cyber-attacks, cyber-vandalism...
View Article10 Bits of Advice for Students Interested in Drug Development
Daniel Sem Here are my 10 crucial pieces of advice for students who aspire to a career in pharmaceutical labs: 1. You need a solid foundation in science. Master the (Read more...)
View ArticleHepatitis C Commercial Game Theory
Peter Kolchinsky Anyone either celebrating or fearing the start of a Hepatitis C drug price war should take a break from the excitement to consider that a far more nuanced (Read more...)
View ArticleImplications of the Oil Price Collapse
Michael A. Greeley Instead of developing a warmed over list of “Top 10 Predictions for 2015,” over the past few months I have been most interested in the implications from (Read more...)
View ArticleEven When Money is Easy, Rules of Biotech Finance Still Apply
Standish Fleming Last month Juno Therapeutics closed a $250 million IPO, bringing the total raised since it was founded in Seattle in 2013 to close to $600 million. The (Read more...)
View ArticleIn Search of a Better Approach to Breast Cancer Screening
David Eichler As a venture investor in the healthcare sector, I see a lot of new medical technologies that promise improvement over the current standard of care. Opportunities that represent (Read...
View ArticleIt had to be you: Why Roche Was the Lone Suitor for Foundation
Steve Dickman The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it (Read more...)
View ArticleClik here to view.
Crowdfunding is Banging on Biotech’s Door. Will We Let It In?
Ros Deegan In the summer of 2013, the medical device startup Scanadu made headlines around the world when Scout, its handheld medical diagnostic tool for consumers, raked in an astounding (Read more...)
View ArticleInnovation Outlook for 2015: Tackling Big Data Variety
Andy Palmer In 2015, look for the innovation community to be talking about Big Data Variety: the problem, how to fix it, how to make money off of it. Companies (Read more...)
View ArticleMilestones of Innovation: Gregor Mendel on Heredity, 1865
Victor McElheny Today, as 150 years ago, for an innovation to happen, the idea it rests on must be understood by the people who hear it. On the 8th (Read more...)
View ArticleResistance Is Futile: Why That’s A Good Thing In Biomedicine
Stewart Lyman Fans of Star Trek: The Next Generation are very familiar with the Borg, a society of cybernetic individuals linked together in a collective mindset. The Borg navigate (Read more...)
View ArticleWhy Boston Biotech Should Look to London
Eliot Forster Look at online forums for U.K. ex-pats working in the Boston-Cambridge biotech sector and you’ll find some very British obsessions—where to find a decent curry and where (Read more...)
View ArticleBet the Jockey…and the Horse…and the Track
Michael A. Greeley Earlier this month we announced a new investment in Iora Health, a fascinating company run by an extraordinary entrepreneur transforming an enormous sector of the healthcare...
View ArticleFor Life Science Industry, Social Media Takes on New Significance
Joan Siefert Rose It seemed like a question out of left field at the time: “How many of you maintain and monitor Twitter, Instagram, Facebook, and Tumblr accounts?” The (Read more...)
View Article
